Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

ChemoCentryx's CCX-168 leads to improvements in patient with C3 glomerulopathy

Oct. 28, 2016

FDA committee votes in favor of approving SER-120 for nocturia

Oct. 24, 2016

FDA accepts NDA resubmission for sodium zirconium cyclosilicate

Oct. 18, 2016

Omeros reports phase II data for OMS-721, pursuing FDA breakthrough therapy designation

Oct. 18, 2016

Phase II results lead NeuroVive to discontinue development of CicloMulsion for acute kidney injury

Oct. 13, 2016

Takeda Pharmaceutical presents EIT6 inhibitors

Oct. 13, 2016

Xenetic Biosciences reports positive data from phase II trial of erepoxen

Oct. 11, 2016

JW Pharmaceutical reports desfesoterodine derivatives

Oct. 10, 2016

Toray Industries prepares and tests agents for urinary incontinence

Oct. 6, 2016

FDA grants orphan drug designation to AbbVie's atrasentan

Oct. 5, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...